H1N1 Vaccines Market Size, Share, Outlook, and Opportunity Analysis, 2019– 2027

H1N1 Vaccines Market Report Analyses competitive environment such as key players, future trends, growths, challenges and acquisitions in the market.
 
SEATTLE - Aug. 4, 2021 - PRLog -- H1N1 Vaccines Market - Regional Insights

North America is expected to lead the H1N1 vaccines market during the forecast period. This is due to increasing government initiatives for prevention of H1N1 infection. U.S. which faced major epidemic in 2009. After this pandemic the U.S. has strengthen the preventive approach to control H1N1 outbreak by implementing vaccination program. According to statistics given by Centre for Disease Control  and Prevention in February 2018, during October 1, 2017 and  February 3, 2018, clinical laboratories tested 666,493 specimens for influenza virus, 124,316 (18.7%) of which tested positive for influenza virus. 84.3% of these tested positive for influenza A.

Furthermore Asia Pacific market is expected to exhibit the highest CAGR due to high prevalence of swine flu and increasing awareness about vaccination against H1N1.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2056

H1N1 influenza virus causes viral disease, commonly known as swine flu, which mostly affects the respiratory system. Swine flu is characterized by infection from H1N1 strain. Symptoms of H1N1 flu are fever, cough, sore throat, runny or stuffy nose, watery and red eyes, body aches, headache, fatigue, and diarrhea. H1N1 spreads through contact with contaminated air or geographical locations infected with virus. H1N1 infection may worsen other chronic respiratory conditions such as bronchitis, pneumonia, COPD, and sometimes even death due to respiratory failure.

H1N1 Vaccines Market - Market Dynamics

One of the major factor propelling growth of H1N1 market is increased incidence of disease and episodes of pandemic worldwide from H1N1 infection. According to World Health Organization's (WHO) 2018, factsheet estimates, 290,000 to 650,000 deaths are reported each year from all types of influenza infection (including Influenza A i.e. H1N1).

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/h1n1-vaccines-market-2056

Furthermore, rising geriatric population worldwide would be another impetus for growth of the H1N1 vaccine market. Global population is crossing the age of 60 at annual rate of 3% according to 2017 UN report. Increased age, maximizes the risk of various respiratory tract related diseases and immune deficient diseases, thereby the risk for infection due to H1N1 virus rises.

H1N1 Vaccines Market - Competitive Landscape

Key players present in the H1N1 vaccines market are Medimmune, AstraZeneca, GlaxoSmithKline, Novartis, Serum Institute of India, Abbott Healthcare, Sanofi Pasture, CSL Biotherapeutics, Sinovac, ID Biomedical Corporation, Cadila Healthcare, and Lupin Ltd.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2056

Contact
Mr. Shah
sales@coherentmarketinsights.com
+1-206-701-6702
End
Source: » Follow
Email:***@coherentmarketinsights.com
Posted By:***@coherentmarketinsights.com Email Verified
Tags:Healthcare
Industry:Health
Location:Seattle - Washington - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Coherent Market Insights News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share